zorevunersen
Phase 3RNA therapy
zorevunersen is one of 5 small molecule programs targeting Dravet syndrome. It is currently in Phase 3.
1
Indications
2
Total Trials
2
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Dravet Syndrome
#DrugCompanyPhaseTrials
1Fintepla
IImmedica Pharma AB
Approved
Fintepla
UCBApproved
zorevunersen
SStoke Therapeutics, Inc
Phase 3
ETX101
EEncoded Therapeutics
Phase 2
Diacomit
BBiocodex
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for zorevunersen. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- RNA therapy[2]
- Highest Phase
- Phase 3[1]
- Company
- SStoke Therapeutics, Inc